guanidine has been researched along with Myasthenia Gravis in 5 studies
Guanidine: A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.
guanidine : An aminocarboxamidine, the parent compound of the guanidines.
Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.
Excerpt | Relevance | Reference |
---|---|---|
"The pharmacokinetic parameters of guanidine hydrochloride were analysed in dogs with an hereditary neuromuscular transmission disorder by the use of 14C-guanidine hydrochloride." | 5.27 | Pharmacokinetics and pharmacodynamics of guanidine hydrochloride in an hereditary myasthenia gravis-like disorder in dogs. ( Flagstad, A; Nielsen, P; Trojaborg, W, 1986) |
"Treatment with guanidine hydrochloride resulted in clinical improvement of the neuromuscular disease, but the patient died of refractory leukemia." | 2.37 | Eaton-Lambert syndrome in a patient with acute T cell lymphocytic leukemia. ( Clinton, ME; Manian, FA; Morrow, JD; Stein, RS, 1988) |
"The pharmacokinetic parameters of guanidine hydrochloride were analysed in dogs with an hereditary neuromuscular transmission disorder by the use of 14C-guanidine hydrochloride." | 1.27 | Pharmacokinetics and pharmacodynamics of guanidine hydrochloride in an hereditary myasthenia gravis-like disorder in dogs. ( Flagstad, A; Nielsen, P; Trojaborg, W, 1986) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
FROKE, LB | 1 |
MARGOSHES, SF | 1 |
HARRELL, GT | 1 |
Riggs, JE | 1 |
Schütte, J | 1 |
Niederle, N | 1 |
Seeber, S | 1 |
Morrow, JD | 1 |
Manian, FA | 1 |
Clinton, ME | 1 |
Stein, RS | 1 |
Flagstad, A | 1 |
Nielsen, P | 1 |
Trojaborg, W | 1 |
2 reviews available for guanidine and Myasthenia Gravis
Article | Year |
---|---|
Pharmacologic enhancement of neuromuscular transmission in myasthenia gravis.
Topics: 4-Aminopyridine; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Ambenonium Chloride; Aminopyr | 1982 |
Eaton-Lambert syndrome in a patient with acute T cell lymphocytic leukemia.
Topics: Aged; Electromyography; Female; Guanidine; Guanidines; Humans; Leukemia-Lymphoma, Adult T-Cell; Medi | 1988 |
3 other studies available for guanidine and Myasthenia Gravis
Article | Year |
---|---|
The role of guanidine in the therapy of myasthenia gravis.
Topics: Guanidine; Guanidines; Humans; Myasthenia Gravis; North Carolina | 1946 |
[Lambert-Eaton syndrome. A contribution to its pathogenesis, diagnosis and therapy].
Topics: Carcinoma, Small Cell; Diagnosis, Differential; Guanidine; Guanidines; Humans; Lung Neoplasms; Male; | 1983 |
Pharmacokinetics and pharmacodynamics of guanidine hydrochloride in an hereditary myasthenia gravis-like disorder in dogs.
Topics: Animals; Carbon Radioisotopes; Dog Diseases; Dogs; Guanidine; Guanidines; Injections, Intravenous; K | 1986 |